Processa (NASDAQ: PCSA) CDO buys 2,107 shares in open-market trade

Rhea-AI Filing Summary

Processa Pharmaceuticals’ Chief Development Officer, Bigora Sian, purchased common stock in the open market. On March 31, 2026, Sian bought 2,107 shares of Processa Pharmaceuticals common stock at $2.535 per share, increasing direct ownership to 3,711 shares. The filing also reports indirect ownership of 267 shares held through CorLyst, LLC.

Insider Trade Summary

Net Buyer: 2,107 shares ($5,341)

Net Buy 2 txns

Insider Bigora Sian

Role Chief Development Officer

Bought 2,107 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,107	$2.535	$5K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,711 shares (Direct); Common Stock — 267 shares (Indirect, By CorLyst, LLC)

Footnotes (1)

Key Figures

Shares purchased: 2,107 shares Purchase price: $2.535 per share Direct holdings after transaction: 3,711 shares +1 more

4 metrics

Shares purchased 2,107 shares Open-market purchase on March 31, 2026

Purchase price $2.535 per share Open-market purchase of common stock

Direct holdings after transaction 3,711 shares Common stock directly owned by Bigora Sian

Indirect holdings 267 shares Common stock held indirectly through CorLyst, LLC

Key Terms

open-market purchase, indirect ownership, Form 4, common stock, +1 more

5 terms

open-market purchase financial

"Sian bought 2,107 shares of common stock in an open-market purchase at $2.535 per share"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"The filing also reports indirect ownership of 267 shares held through CorLyst, LLC"

Form 4 regulatory

"as disclosed in the Form 4 insider trading report filed with regulators"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

common stock financial

"purchased 2,107 shares of Processa Pharmaceuticals common stock at $2.535 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Chief Development Officer financial

"Processa Pharmaceuticals’ Chief Development Officer, Bigora Sian, purchased common stock in the open market"

Chief development officer is the senior executive who leads a company's efforts to create and grow future revenue streams, whether by developing new products, forging partnerships, or running clinical and regulatory programs in research-focused businesses. Investors watch this role because the officer shapes the pipeline and execution that determine future sales and risk — like a head gardener planning and tending crops that will produce tomorrow’s harvest.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bigora Sian

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		P		2,107	A	$2.535	3,711	D
Common Stock								267	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Sian Bigora by John J. Wolfel, as Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA executive Bigora Sian report?

Bigora Sian reported an open-market purchase of Processa Pharmaceuticals common stock. On March 31, 2026, Sian bought 2,107 shares, increasing direct ownership and signaling additional personal capital committed to the company’s equity.

How many Processa Pharmaceuticals (PCSA) shares did Bigora Sian buy and at what price?

Bigora Sian bought 2,107 shares of Processa Pharmaceuticals common stock. The open-market purchase was executed at a price of $2.535 per share, as disclosed in the Form 4 insider trading report filed with regulators.

What are Bigora Sian’s total direct PCSA share holdings after this transaction?

After the reported open-market purchase, Bigora Sian directly owns 3,711 shares of Processa Pharmaceuticals common stock. This post-transaction figure reflects Sian’s direct stake, excluding any additional indirect holdings reported through affiliated entities.

Does Bigora Sian have any indirect ownership of Processa Pharmaceuticals (PCSA) shares?

Yes. In addition to directly held shares, the filing reports indirect ownership of 267 Processa Pharmaceuticals common shares held through CorLyst, LLC. This separate line item reflects shares attributed to Sian via that affiliated entity.

What does an open-market purchase by a Processa Pharmaceuticals officer typically indicate?

An open-market purchase means the officer bought shares on the public market at prevailing prices. It represents the executive committing personal funds to acquire stock, rather than receiving shares through compensation awards or option exercises.